Interleukin (IL)-15 and its receptors are induced by tumor necrosis factor (TNF) in the cerebral endothelial cells composing the blood-brain barrier, but it is not yet clear how IL-15 modulates endothelial function. Contrary to the known induction of JAK/ STAT3 signaling, here we found that nuclear factor (NF)-B is mainly responsible for IL-15 actions on primary brain microvessel endothelial cells and cerebral endothelial cell lines. IL-15-induced transactivation of an NF B luciferase reporter resulted in phosphorylation and degradation of the inhibitory subunit I B that was followed by phosphorylation and nuclear translocation of the p65 subunit of NF B. An I B kinase inhibitor Bay 11-7082 only partially inhibited IL-15-induced NF B luciferase activity. The effect of IL-15 was mediated by its specific receptor IL-15R , since endothelia from IL-15R knockout mice showed delayed nuclear translocation of p65, whereas those from knockout mice lacking a co-receptor IL-2R did not show such changes. At the mRNA level, IL-15 and TNF showed similar effects in decreasing the tight junction protein claudin-2 and increasing the p65 subunit of NF B but exerted different regulation on caveolin-1 and vimentin. Taken together, NF B is a major signal transducer by which IL-15 affects cellular permeability, endocytosis, and intracellular trafficking at the level of the blood-brain barrier.
Introduction
Interleukin (IL)-15 is a ubiquitously expressed 14 kD cytokine. It binds to its unique receptor IL-15R as well as two co-receptors IL-2R (also termed IL-15R ) and IL-2R common chain. This heterotrimeric receptor complex is the high affinity form that activates Janus kinase (JAK) and Signal Transducer and Activator for Transcription (STAT) proteins [1] [2] [3] [4] [5] [6] . In most cells the actions of IL-15 are mediated through the JAK/STAT pathway; however, little is known about IL-15-activated signaling in the microvascular endothelial cells that compose the blood-brain barrier (BBB).
Blood IL-15 levels are low in the resting state but increase after inflammatory and autoimmune challenges. 116 In endothelia of mouse cerebral microvessels and cultured rat brain endothelial (RBE)-4 endothelial cells, tumor necrosis factor (TNF) stimulates both IL-15 and IL-15 receptor expression [7] . Similarly, the mRNA of all three IL-15 receptor subunits (IL-15R , IL-2R , IL-2R ) in both cerebral microvessels and CNS parenchyma can be increased by lipopolysaccharide (LPS), a prototypic inflammatory stimulus that activates TNF and other proinflammatory cytokines, as well as by experimental autoimmune encephalomyelopathy (EAE) [8, 9] . In mice with EAE, IL-15 treatment provides neuroprotection and reduces behavioral deficits. Thus, we further hypothesize that IL-15 signaling in endothelial cells exerts cytoprotective effects against inflammation and impaired function of the BBB.
The master regulator of gene expression in inflammation is nuclear factor B (NF B/Rel). There are five members of the Rel family that can homo-and/ or heterodimerize with each other: p65/RelA, RelB, c-Rel, p50, and p52. Dimerization and nuclear translocation are tightly controlled by a family of inhibitory molecules (I B) that keep NF B in the cytoplasm [10] . TNF induces NF B through a signaling cascade that includes binding to the TNF receptor (TNFR), binding of TNFR associated factor (TRAF)-2, activation of I B kinase (IKK), phosphorylation and proteasomal degradation of I B, dimerization and nuclear translocation of NF B, and activation of gene expression by binding to cognate DNA binding sites [11, 12] .
Thus, there are at least two potential models of TNF/IL-15 interactions within cerebral endothelia: (a) signaling crosstalk of TNF-induced NF B and IL-15-activated STAT3 and STAT5, as shown with a few other classes of receptors [13] , or (b) convergence or antagonism of TNF and IL-15 signaling at NF B. Both novel hypotheses could illustrate important principles in endothelial cell biology.
Materials und Methods
Cells RBE4 cells of rat brain microvessel endothelial cell origin and hCMEC/D3 cells of human brain microvessel cell origin were both kindly provided by Dr. Pierre-Olivier Couraud (Institut Cochin, Paris, France). The cells were plated onto plates coated with collagen (50µg/ml). RBE4 cells were cultured in MEM/ Ham's F10 (1:1; Invitrogen, Carlsbad, CA) supplemented with 10% FBS (heat-inactivated; Invitrogen), FGF (1 ng/ml; Invitrogen), and G418 (30 µg/ml; Invitrogen). hCMEC/D3 cells were cultured in EBM-2 media (Lonza, Basel, Switzerland) containing all provided supplements but without heparin.
Primary mouse brain microvessel endothelial cells (PBMEC) were isolated from brain cortices of wild-type or IL-15 receptor knockout (KO) mice following an approved Institutional Animal Care and Use protocol as previously described [14] . This includes 4-6 week old, IL-15R KO and matching B6129SF2/J controls, and IL-2R KO and matching B6 controls, all from Jackson Laboratories (Bar Harbor, ME).
Transfection experiments RBE4 cells were plated onto a 48-well plate. Twenty-four h later, the STAT3 luciferase reporter (0.1µg/well; kindly provided by Dr. Charles Rosenblum, Merck Research Laboratories, Rahway, NJ), the STAT5 luciferase reporter (0.1µg/ well; kindly provided by Dr. Charles V. Clevenger, Northwestern University, Chicago, IL), or the NF B luciferase reporter (0.1µg/ well; Agilent Technologies, Santa Clara, CA) combined with a Renilla luciferase (10ng/well; Promega, Madison, WI) as an internal reference plasmid were transfected into 95% confluent cells by use of lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Transfection of RBE4 cells with GFP plasmids in similar concentrations showed that about 80-90% of cells were transfected. Twenty-four h after transfection and 12 h of serum-starvation, the cells were treated for 6 h with either IL-15 (Peprotech, Rocky Hill, NJ) or TNF (5 ng/ml), or a combination of both as indicated. To test the role of IKK, p38 mitogen-activated protein kinase (MAPK), and Akt on TNF and IL-15-induced NF B transactivation, we used the inhibitors Bay 11-7082 (Bay; 10 µM; EMD Chemicals, Gibbstown, NJ) and SB203580 (30 µM; Santa Cruz, Santa Cruz, CA) . Cells transfected with the NF B luciferase reporter were treated for 6 h along with cytokines, and compared with a DMSO vehicle control studied concomitantly. Luminescence was detected by the Dual luciferase assay (Promega) according to the manufacturer's instructions. STAT3, STAT5, and NF B luciferase activities were normalized by Renilla control luciferase activity. All groups contained triplicated wells, and each result was at least duplicated.
Immunocytochemistry and Western blot analysis hCMEC/D3 and PBMEC cells were plated onto 8-well chambered Permanox slides (Thermo Fisher Scientific, Pittsburgh, PA) for immunocytochemistry and confluent cells then were incubated for 5, 15, or 30 min with human IL-15 (5 ng/ml; Peprotech). For immunocytochemistry, cells were fixed with 4% paraformaldehyde and then washed with phosphatebuffered saline (PBS), permeabilized for 30 min in PBS/0.1% Triton X-100, and blocked for 1 h in 10% normal donkey serum in PBS. Fixed cells were incubated overnight at 4°C with mouse anti p65 (1:50; sc-8008; Santa Cruz) diluted in PBS/0.1% Triton X-100/1% BSA. Then cells were washed three times with PBS for 5 min and incubated with Alexa488-conjugated anti-mouse secondary antibody (1:1000; Invitrogen) for 1 h. After a thorough wash, slides were mounted with Vectashield mounting media containing DAPI (Vector Laboratories, Burlingame, CA). Immunofluorescence was captured on either an Olympus FV1000 inverted laser scanning microscope or a Zeiss Axioplan 2 fluorescence microscope connected to a Photometrics CoolSnap HQ CCD camera. For western blot analysis, hCMEC/D3 cells were plated onto 6-well plates. For control, one well was pretreated for 1 h with mouse anti IL-15 antibody (1:100; sc-8437; Santa Cruz), and other wells were treated with either human TNF (5 ng/ml; Peprotech) or IL-15 for 5 and 15 min. Similar experiments were performed in the presence of goat anti-TNF antibody (1:100; sc-1351; Santa Cruz) in all wells. Cells were lysed with Cellytic (Sigma) and protein concentration was measured by the BCA method (Pierce). Lysates were electrophoresed on an SDS gel and transfered onto a nitrocellulose membrane. After being blocked with PBS-T/5% milk, membranes were incubated with rabbit anti-pp65 (1:2000; ab31472; Abcam; Cambridge, UK), mouse anti-pI B (#9246), rabbit anti-pSTAT3 (#9131), or rabbit anti-pSTAT5 (#9359) antibodies (1:2000, all from Cell Signaling, Danvers, MA) overnight at 4°C. After being washed, membranes were incubated with either anti-mouse HRP or anti-rabbit HRP (1:5000; Perkin Elmer, Boston, MA), and proteins were visualized by use of ECL substrate (Amersham). Then, membranes were stripped with Restore stripping buffer (Pierce) and incubated with either mouse anti-p65 (1:500; sc-8008, Santa Cruz), rabbit anti-I B (1:2000; #9242, Cell signaling), rabbit anti-STAT3 (1:1000; 06-596, Millipore), or rabbit anti-STAT5 antibodies (1:1000; sc-835, Santa Cruz) overnight at 4°C. After additional stripping, the I B blot was incubated with mouse anti--actin antibody (1:10000; A5441, Sigma, St. Louis, MO). Membranes were washed, incubated with secondary antibodies, and proteins were visualized as described above. qPCR hCMEC/D3 cells (passage # 31-33) were plated onto 6-well plates and incubated for 6 h with either human TNF (5 ng/ml) or human IL-15 (5 ng/ml). Then, mRNA was isolated by use of the ChargeSwitch kit according to the manufacturer's instructions (Invitrogen). mRNA was reverse transcribed with a Superscript RT kit with Oligo dT primers according to the manufacturer's instructions. cDNA concentrations were measured and 50 ng cDNA was used together with genespecific primers (Table 1) and SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) for qPCR on an ABI7900T. Induction of gene expression was determined by the CT method.
Statistical Analysis
Means were presented with their standard errors. Oneway ANOVA was performed to determine overall difference among groups, followed by Tukey's post-hoc test where appropriate.
Results

IL-15 is a robust inducer of NF B activation
It is usually thought that IL-15 signals through STAT3 and STAT5 whereas TNF activates NF B as well as many other pathways. We tested the activation by IL-15 of both a STAT3 and a STAT5 luciferase reporter in RBE4 cells. STAT3 luciferase reporter induction by IL-15 (100 ng/ml) was not significant (Fig. 1A) . Similarly, endogenous phosphorylation of STAT3 was not induced by IL-15 beyond the basal state in another brain microvessel endothelial cell line, the hCMEC/D3 cells (Fig.  1B) . To test the hypothesis that TNF and IL-15 interact Fig. 2A) , whereas TNF had no effect on reporter activity. Endogenous STAT5 in hCMEC/D3 cells was phosphorylated within 5 min after IL-15 treatment and persisted for 15 min (Fig. 2B) . Unexpectedly, IL-15 alone was sufficient to induce NF B transcriptional activation in RBE4 cells as shown by the NF B luciferase reporter assay. TNF was also effective in inducing NF B transcriptional activation. We used 5 ng/ml of TNF since higher doses are known to impair cellular ATP production and cause cytotoxicity in RBE4 cells [15] . However, the combination of TNF and IL-15 did not induce a further increase of NF B luciferase activity (Fig. 3A) . Dose-response studies showed that 1 ng/ml of IL-15 exerted maximal effect, and there was no additional increase in the group treated with 5-100 ng/ml of IL-15 (Fig. 3B) . Since the NF B luciferase reporter we used contains only five copies of the B DNA binding site, IL-15 must activate signaling pathways that result in binding of NF B to its DNA binding site. Therefore, we next tested whether IL-15 induces nuclear translocation of p65, which showed cytoplasmic distribution in hCMEC/D3 cells pretreated with a neutralizing anti-IL-15 antibody. Treatment with IL-15 (5 ng/ml), however, resulted in nuclear translocation of p65 within 15 min. This persisted at 30 min after treatment (Fig. 4A) . Fig. 2. IL-15 activates STAT5. (A) RBE4 cells transfected with a STAT5 luciferase reporter were treated with IL-15 (100 ng/ml; light bars) in the presence and absence of TNF as indicated (dark bars). Whereas IL-15 induced STAT5 luciferase activity (*p < 0.05, ***p<0.005), TNF had no effect. The graph is representative of two independent experiments, n=3/data point. (B) hCMEC/D3 cells were treated with IL-15 (100 ng/ml) for the indicated times and extracts were exposed to western blot analysis. Endogenous STAT5 was phosphorylated within 5 min. Similar results were obtained with RBE4 cells. Results shown are representative of each two independent experiments with hCMEC/D3 and RBE4 cells. 
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Phosphorylation of p65 typically precedes nuclear translocation. In hCMEC/D3 cells, IL-15 induced phosphorylation of p65 within 15 min, as did TNF (Fig.4B , upper panel). TNF-induced but not IL-15-induced phosphorylation of p65 was abolished in the presence of a TNF neutralizing antibody, indicating the direct activation of p65 by IL-15 (Fig. 4B, lower panel) .
TNF-induced activation of NF B is preceded by phosphorylation and degradation of I B. To determine whether IL-15 uses a pathway similar to TNF for activation of NF B, we next determined expression of phosphorylated I B in hCMEC/D3 extracts. As shown in Fig. 4C , both IL-15 and TNF induced phosphorylation and partial degradation of I B within 5 and 15 min, respectively.
is mainly phosphorylated by IKK but p38 MAPK and Akt also may play a role in IL-15 mediated activation of NF B. Therefore, we performed transactivation assays in the presence of inhibitors. Treatment with the IKK inhibitor Bay increased basal transcriptional activity by 45%. As expected, Bay significantly inhibited TNF-induced NF B activation by 74%, whereas IL-15-induced NF B activation was only inhibited by 25% (Fig. 5) . At the concentration used, SB203580 inhibited both p38 MAPK and Akt. Inhibitor treatment increased basal transcriptional activity by 40%. Whereas SB203580 had no significant effect on TNF-induced NF B activation (-9%), it inhibited IL-15-induced NF B activation by 48%. Taken together, these results indicate that IL-15 uses pathways downstream of I B phosphorylation similar to TNF, whereas upstream pathways may differ.
Role of the specific receptor IL-15R
IL-15 activates signaling through its receptors IL-15R , IL-2R , and IL-2R , with IL-15R being the high affinity receptor, and IL-2R /IL-2R acting as low affinity receptors. Most signaling requires the IL-2R / IL-2R dimer. To explore which receptor units are required for activation of NF B, we used primary microvessel endothelial cells from mice genetically modified to lack either IL-15R or IL-2R and their age-matched controls. Treatment with TNF and IL-15 for the indicated time confirmed that p65 translocates into the nucleus of endothelial cells from wild-type mice within 15 minutes, similar to that seen in hCMEC/D3 cells (Figs. 6A and B) . Whereas p65 was found in nuclei of cells lacking IL-2R within 15 minutes (Fig. 6B) , p65 translocation took 30 minutes in cells lacking IL-15R (Fig. 6A) . These results indicate that IL-15R plays a role in IL-15-mediated NF B activation.
Effects of IL-15-induced NF B activation on endothelial functions
To determine how IL-15 modulates endothelial functions, hCMEC/D3 cells were subjected to IL-15 treatment for 6 h and the gene expression profile related to NF B activation was analyzed by qPCR. Besides the PBS vehicle control, an additional group of cells received TNF treatment for comparison with IL-15. Since TNF increases the expression of IL-15 and IL-15R which may in turn regulate genes required for endothelial TNF signaling, we first measured expression of the p65 subunit of NF B, TNFR1, TNFR2, and the TNFR associated factor 2 (TRAF2) known to also bind IL-15R [16] . Among these genes, p65 and TNFR2 promoters have NF B binding sites and TRAF2 is regulated by NF B [17] . We found that both TNF and IL-15 up-regulate p65 expression (Fig. 7, upper panel) . Both TNF and IL-15 decreased TNFR1 and increased TNFR2 expression, but the effects were not significant. Whereas TNF had no effect, IL-15 tended to increase TRAF2 expression.
Next, we determined the levels of expression of a set of genes related to endothelial functions, including maintenance of BBB properties. This list includes junctionassociated proteins and transport proteins. Among them, caveolin [18] , claudin-2 [19] , and vimentin [20] expression is regulated by NF B, whereas occludin and zona occludin (ZO)-2 expression is not. We found that IL-15 significantly decreased and TNF abolished the expression of claudin-2, whereas neither significantly affected expression of occludin or ZO-2 (Fig. 7, center panel) . However, expression of caveolin was only affected by TNF, whereas expression of vimentin was only affected by IL-15 (Fig. 7, lower panel) .
Western blot analysis of p65, TRAF2, caveolin, and vimentin expression in hCMEC/D3 cells after 6, 12, and 24 h treatment with either IL-15 or TNF did not show significant changes in protein expression (data not shown). Taken together, these results indicate that IL-15 plays a role in transcriptional control of p65 and in selective regulation of NF B target genes.
Discussion
We show here that IL-15 activates an NF B luciferase reporter, and regulates the transcription of p65 as well as of junction-associated and cytoskeletal proteins in brain microvessel endothelial cells. IL-15 is a powerful antagonist of TNF's pro-apoptotic functions since IL-15 deflects TRAF2 from the TNF receptor toward the IL-15R chain [21] . By contrast, we showed that IL-15 induced NF B activation and nuclear translocation. The results demonstrate that IL-15 induces NF B target genes both similarly and differently from TNF.
Our results indicate that IL-15R plays a role in IL-15-induced NF B activation. IL-15 recruits TRAF2 to IL-15R [21] , but IL-2R and IL-2R are not involved. Variations in the strengths of the interaction between TRAF2 and IL-15R have been shown in two different melanoma cell lines [16] . This may explain why in some cells but not others IL-15 can induce NF B [22] . There are multiple pathways that can lead to phosphorylation of I B. In contrast to TNF, IL-15-induced activation of NF B was only partially inhibited by the IKK inhibitor BAY, indicating a role of alternative kinases for IL-15-mediated phosphorylation of I B.
NF B can also be activated through p38 MAPK and Akt-mediated pathways [23, 24] . IL-1 requires Akt to induce NF B in an IKK-and p38 MAPK-dependent manner [25] . IL-15 could potentially induce p38 MAPK and Akt through scaffolding proteins interacting with either IL-2R or STAT5 [26, 27] . We found that an inhibitor of both p38 MAPK and Akt partially inhibits IL-15-induced NF B transactivation, indicating a role of kinases other than IKK in I B phosphorylation. The activation of p38 MAPK and NF B in cerebral endothelia by IL-15 is similar to that shown in stimulated microglia [28] .
NF B regulates the proinflammatory response in endothelial cells [29] . TNF activates NF B mainly by TNFR2-mediated pathways, whereas TNF binding to TNFR1 can induce apoptosis. IL-15 is known to protect
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Cell Physiol Biochem 2011; 28:115-124 various types of cells from TNF-induced apoptosis [30] [31] [32] [33] [34] ; this may involve activation of NF B [16, 35] . TNFR2 and TRAF2 play a role in diverting TNF actions from death-receptor mediated apoptosis to NF B activation [36, 37] . Our findings show that IL-15 increases the expression of p65 and TRAF2, which may be another mechanism contributing to its anti-apoptotic properties. Although IL-2 and IL-15 share common IL-2R /IL-2R receptor units, this effect is specific for IL-15, as IL-2 does not activate NF B in neutrophils [38] . The BBB is a unique structure composed by specialized endothelial cells joined by tight junctions, underlaid by a continuous basement membrane, and reinforced by other cellular components such as astrocytic endfeet, pericytes, and microglia [39, 40] . The BBB responds to inflammation with increased cytokine production, activation of transport proteins such as caveolin [41] , increased permeability, and selective upregulation of cytokine transport [42, 43] . NF B plays a role in these changes, and this may be mediated by target gene products such as caveolin-1 [18] and the tight junction protein claudin-2 [44] . Beyond inflammatory signaling affecting tight junction proteins, NF B may also influence endothelial functions by regulating target gene products such as vimentin [20] , an intracellular intermediate filament contributing to endothelial cell shape and implicated in formation of invadopodia [45, 46] . Thus, comparison of the effects of TNF and IL-15 on the target genes regulating BBB functions shows that the effects of NF B activation may be cytokine-specific.
Since NF B is a transcription factor shared by TNF and IL-15, we determined the target genes in cerebral endothelia that are potential targets of regulation by both cytokines. Among the genes tested, claudin-2, known to be regulated by NF B, was decreased by both TNF and IL-15, but vimentin and caveolin were differentially regulated. This indicates that transcription factors other than NF B may play a more important role in the expression of these proteins. For example, the promoter of the caveolin gene contains both an NF B and a STAT5 binding site, so that IL-15 might act through both transcription factors to regulate caveolin.
The expression profile of tight junction proteins in hCMEC/D3 cerebral endothelial cells differs from that in intestinal cells in response to IL-15. In our study, IL-15 had no effect on ZO-2 expression. In the human intestinal epithelial cell line T-84, IL-15 up-regulates ZO-2 independently of IL-2R but facilitates the functions of occludin and claudins by IL-2R [47] . We showed that TNF suppressed claudin-2 expression in cerebral endothelia; however, TNF acts through NF B and increases claudin-2 in HT-29/B6 human colon cells [44] . Nonetheless, the TNF-induced increase of caveolin [48] and decrease of occludin expression in endothelial cells [49] is consistent with our results. We chose the hCMEC/ D3 cell line as a model system since TNF activates NF B in these cells and they express TNF receptors [50, 51] . Overall, there is cell type specific regulation of junctional proteins.
Another novel finding is that IL-15 decreases vimentin expression. Vimentin is an intermediate filament important for the three-dimensional structure of endothelial cells. In astrocytes, vimentin also plays a role in vesicular trafficking [52] . During hypoxia, expression of vimentin increases in brain microvessel endothelial cells [53] . Similar to our results, TNF caused no change in vimentin expression in bovine cerebral microvessel endothelia [54] . Thus, IL-15 may act both as a mediator and an antagonist of TNF actions though it is produced in response to TNF.
An unusual finding is that TNF co-treatment with IL-15 increased activation of the STAT3 but not of the STAT5 luciferase reporter. Since TNF and IL-15 cotreatment did not induce STAT3 phosphorylation within minutes, the increase in STAT3 activation is probably indirect. The effect of TNF on IL-15-mediated activation of STAT3 is most pronounced after 12 h pretreatment, which may be explained by the inducing effect of TNF on IL-15 and IL-2R expression in RBE4 cells [7] . This TNF-mediated increase in STAT3 activation may result in the regulation of genes important for functions of brain microvessel endothelial cells by IL-15.
Taken together, in brain microvessel endothelial cells IL-15 can induce both STAT5 and NF B. Activation of NF B appears to be more sensitive to low concentrations of IL-15 and TNF does not have cumulative or additional effects on STAT5 and NF B activation by IL-15. By contrast, TNF affects IL-15-dependent STAT3 activation. These results indicate a complex but specific crosstalk between TNF-and IL-15-induced signaling in brain microvessel endothelial cells. Endothelial signaling is an integral part of the BBB response to cytokines, and it plays an essential role in modulation of CNS functions. Besides illustrating that NF B is an unexpected mediator for IL-15 signaling at the level of the BBB endothelia, we showed that IL-15 signaling modifies the actions of TNF. Since upregulation of the IL-15 system is a major inflammatory response of the BBB endothelia to TNF [7] , IL-15 signaling appears to provide feedback control for TNF function. This indicates a dynamic regulation of BBB functions. 
